Zhong Wang
12
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Post-marketing Safety and Efficacy Surveillance of Motherwort Injection
Role: lead
Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
Role: lead
Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome)
Role: lead
Yinhu Qingwen Granule in the Treatment of Viral Pneumonia
Role: lead
Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
Role: lead
Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
Role: lead
Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study
Role: lead
Effect of Zhuli Capsule on Phlegm-heat Syndrome (Tan-re Zheng)
Role: lead
Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma
Role: lead
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Role: lead
Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea
Role: lead
Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
Role: lead
All 12 trials loaded